Qiagen N.V. QIA.DE
Composite 55/100; the shares have moved about 35% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 40/100 — a slight mark against it.
Balance-sheet strength ranks 70/100 — a moderate point in its favour. Quality ranks 65/100 — a moderate point in its favour. Valuation ranks 52/100 — a slight point in its favour.
Momentum ranks 40/100 — a slight mark against it. Income ranks 42/100 — a slight mark against it. Growth ranks 42/100 — a slight mark against it.
What the company does Qiagen N.V. (QIA.DE) provides sample-to-insight solutions, transforming biological samples into molecular insights through consumables and instruments for nucleic acid analysis, diagnostics, and research applications.
Key financials Revenue growth is modest at 1.8%, while EPS declined -23.8%. Margins remain robust: gross 66.1%, operating 23.8%, and net 19.2%. Profitability metrics include ROE 11.9%, ROA 6.0%, and ROCE 9.7%.
Stock health Strength pillar scores 80.3/100, indicating strong financial health. The Piotroski F-Score is 7/9 and Altman Z is 3.42, suggesting low bankruptcy risk. However, momentum is weak with 12-month performance at -14.92%.
Price vs fair value The stock trades at a **discount** of 15.60% to our fair-value estimate and a **discount** of 4.10% to the analyst 12-month target. - Analysts estimate earnings decline ahead (Zacks) - Recent competitor earnings beats may pressure sentiment (Zacks) - Valuation percentile 48.7/100 reflects fair valuation
Looking forward Forward P/E of 13.09 and PEG of 0.21 suggest potential undervaluation if growth rebounds. However, growth pillar scores 33.1, indicating weaker growth prospects. Monitor earnings trajectory and margin stability.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.